Absence of galectin-3 does not affect the development of experimental tongue carcinomas in mice

Experimental and Molecular Pathology

Volumn 90, Issue 2, 2011, Pages 189-193

  de Faria, Paulo Rogério ^a,b   Chammas, Roger ^c   de Melo, Thaissa Lopes ^b   Hsu, Daniel K ^d   Liu, Fu Tong ^d   Nonogaki, Suely ^e   Cardoso, Sérgio Vitorino ^b   Loyola, Adriano Mota ^b  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Galectin 3; Mice; Oral carcinogenesis; Oral squamous cell carcinoma; Premalignant lesions; Tongue

Indexed keywords

GALECTIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; DYSPLASIA; EXPERIMENTAL NEOPLASM; MALE; MOUSE; NONHUMAN; PRECANCER; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; TONGUE CARCINOMA; TONGUE DYSPLASIA; WILD TYPE;

ANIMALS; GALECTIN 3; IMMUNOHISTOCHEMISTRY; MICE; PRECANCEROUS CONDITIONS; TONGUE NEOPLASMS;

MUS;

EID: 78651231163     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.12.007     Document Type: Article

References (28)

1. Abdel-Aziz H.O., et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study. J. Cancer Res. Clin. Oncol. 2008, 134:777-788.
2. Betka J., et al. Galectin-3, an endogenous lectin, as a tool for monitoring cell differentiation in head and neck carcinomas with implications for lectin-glycan functionality. Acta Otolaryngol. 2003, 123:261-263.
3. Bresalier R.S. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 1997, 80:776-787.
4. Brustmann H. Galectin-3 and CD1a-positive dendritic cells are involved in the development of an invasive phenotype in vulvar squamous lesions. Int. J. Gynecol. Pathol. 2006, 25:30-37.
5. Castronovo V., et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J. Pathol. 1996, 179:43-48.
6. Cvejic D., et al. Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma. Exp. Oncol. 2005, 27:210-214.
7. Dumic J., et al. Galectin-3: an open-ended story. Biochim. Biophys. Acta 2006, 1760:616-635.
8. Eude-Le Parco I., et al. Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. Glycobiology 2009, 19:68-75.
9. Gillenwater A., et al. Expression of galectins in head and neck squamous cell carcinoma. Head Neck 1996, 18:422-432.
10. Honjo Y., et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin. Cancer Res. 2000, 6:4635-4640.
11. Hsu D.K., et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am. J. Pathol. 2000, 156:1073-1083.
12. Lahm H., et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 2001, 127:375-386.
13. Lee J.W., et al. Decreased galectin-3 expression during the progression of cervical neoplasia. J. Cancer Res. Clin. Oncol. 2006, 132:241-247.
14. Liu F.T., Rabinovich G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005, 5:29-41.
15. Lumerman H., et al. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1995, 79:321-329.
16. Mathieu A., et al. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung. Mod. Pathol. 2005, 18:1264-1271.
17. Piantelli M., et al. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J. Clin. Oncol. 2002, 20:3850-3856.
18. Plzák J., et al. Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma. Eur. J. Cancer 2004, 40:2324-2330.
19. Puglisi F., et al. Galectin-3 expression in non-small cell lung carcinoma. Cancer Lett. 2004, 212:233-239.
20. Saussez S., et al. Galectin-3 upregulation during tumor progression in head and neck cancer. Laryngoscope 2008, 118:1583-1590.
21. Shibata T., et al. Impact of nuclear galectin-3 expression on histological differentiation and vascular invasion in patients with esophageal squamous cell carcinoma. Oncol. Rep. 2005, 13:235-239.
22. Slootweg P.J., Eveson J.W. Tumors of the hypopharynx, larynx and trachea. Pathology and Genetics of Head and Neck Tumors 2005, 118-121. I.A.R.C. Press, Lyon. L. Barnes, J.W. Eveson, P. Reichart, D. Sidransky (Eds.).
23. Takenaka Y., et al. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett. 2003, 195:111-119.
24. Tang X.H., et al. Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin. Cancer Res. 2004, 10:301-313.
25. Vairaktaris E., et al. The hamster model of sequential oral oncogenesis. Oral Oncol. 2008, 44:315-324.
26. van den Brûle F., et al. Expression of galectins in cancer: a critical review. Glycoconj. J. 2004, 19:537-542.
27. Vereecken P., et al. Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch. Dermatol. Res. 2005, 296:353-358.
28. Weinberger P.M., et al. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 2007, 133:503-510.